Ann Arbor, MI and Philadelphia, PA---April 2, 2008---SensiGen LLC, a biotechnology company focused on developing proprietary gene-based molecular diagnostics announced today that the Company was named "Best Life Sciences Company" at the 2008 Venture Conference hosted by the New Jersey Technology Council (NJTC), a nationally recognized non-profit industry association dedicated to supporting technology and business development in the State of New Jersey. SensiGen was selected for this prestigious award from a pool of more than 50 high profile Life Sciences companies invited to present at the conference.

"We are extremely honored to receive this prestigious award", said Shawn M. Marcell, President and CEO of SensiGen. "To be singled out from such a distinguished and successful peer group is indeed a significant honor."

SensiGen's breakthrough molecular diagnostic technology was developed by Dr. David Kurnit in his laboratory at the University of Michigan. The Company’s products are based on the coupling of Polymerase Chain Reaction (PCR) techniques with Mass Spectrometry (MS) to achieve unprecedented levels of sensitivity and specificity in pinpointing the biomarkers that signal the onset of major diseases or the pathogens that cause them. Since its founding in 2004, the Company has raised $4 million in seed funding from a variety of sources, and is currently negotiating a Series A investment round with venture investors.

"SensiGen has all the key elements in place that are necessary for success in the Life Sciences market – truly novel technology, experienced management, a realistic plan, and committed investors", said Maxine Ballen, NJTC President and CEO. "We think SensiGen is poised for significant growth and success in the near future."

About SensiGen, LLC: SensiGen is a biotechnology company focused on gene-based molecular diagnostics. The Company develops advanced technologies to enable early detection of diseases, aimed at improving standards of care and reducing overall health care costs. Current products in development include tests for early detection of human papillomavirus (HPV), the primary cause of cervical cancer, chronic kidney disease (CKD), Crohn's disease, Lupus, and others. SensiGen's proprietary molecular diagnostic assays offer dramatic improvements over current methods.

About The New Jersey Technology Council: The New Jersey Technology Council provides business support, networking opportunities, information, advocacy, and recognition of technology companies and their leaders. Founded in 1996, NJTC's more than 1,200 member companies work together to support their own enterprises while advancing New Jersey's status as a leading technology center in the United States. www.njtc.org.